SMS Pharmaceuticals Share News - Latest Updates, Live News & More

Latest news about SMS Pharmaceuticals

SMS Pharma's Hyderabad Lab Receives FDA Clearance with 'No Action Indicated' Status 10 days ago

SMS Pharmaceuticals Limited announced receipt of an Establishment Inspection Report (EIR) from the U.S. FDA for its Central Laboratory Analytical Services facility in Hyderabad. The inspection concluded with a 'No Action Indicated' (NAI) status, the most favorable outcome possible. This signifies the facility meets FDA's quality and compliance standards, allowing operational continuity without need for corrective actions. The NAI status enhances SMS Pharma's regulatory confidence, market reputation, and ability to serve the U.S. market.

SMS Pharma Receives 'No Action Indicated' Status from USFDA for Hyderabad Laboratory Aug 26, 2025

Vistra ITCL Boosts Stake in SMS Pharmaceuticals to 24.91% Through Share Pledge Aug 25, 2025

SMS Pharmaceuticals Reports Robust Q1FY26 Results: 24% PAT Growth, 19% Revenue Surge Aug 13, 2025

SMS Pharmaceuticals Reports 19% Revenue Growth and 24% PAT Increase in Q1 Aug 11, 2025

More news about SMS Pharmaceuticals

11Aug 25

SMS Pharmaceuticals Sets Ambitious Targets Amid Strong Q1 Performance

SMS Pharmaceuticals reported robust Q1 results with 19% YoY revenue growth to ₹196.05 crore, 17% EBITDA growth to ₹39.37 crore, and 24% PAT growth to ₹20.50 crore. The company aims for 20% annual revenue growth, EBITDA margin above 20%, and 1X asset turnover ratio. A ₹250 crore expansion program is planned to support growth, including capacity expansion, R&D investment, and CDMO site development. Key growth drivers include a diversified product portfolio, increased Ibuprofen demand, successful backward integration, and plans to double R&D spending.

09Aug 25

SMS Pharmaceuticals Reports Strong Q1 Results and No Deviation in Preferential Issue Fund Utilization

SMS Pharmaceuticals announced impressive Q1 financial results with revenue increasing to Rs. 19,604.71 crore from Rs. 16,445.13 crore year-over-year. Net profit rose to Rs. 2,049.05 crore from Rs. 1,647.94 crore. The company confirmed no deviation in the utilization of funds raised through a preferential issue of convertible warrants. Out of Rs. 114.30 crore raised, Rs. 17.14 crore was used for capital expenditure and Rs. 49.53 crore for working capital as of June 30. The 37th AGM is scheduled for September 29, with September 22 set as the record date for dividend eligibility.

09Aug 25

SMS Pharmaceuticals Reports Robust Q1 Results with 19.2% Revenue Growth

SMS Pharmaceuticals achieved strong Q1 results with consolidated revenue up 19.2% to Rs 196.05 crores and net profit rising 24.3% to Rs 20.49 crores. Standalone revenue grew 19.2% to Rs 196.05 crores, while standalone net profit increased 11.5% to Rs 18.21 crores. EBITDA margin slightly decreased to 20.1% from 21.2% year-over-year. The company's associate, VKT Pharma Private Limited, reported revenue of Rs 58.87 crores and net profit of Rs 5.10 crores. The 37th AGM is scheduled for September 29, with the dividend record date set for September 22.

27Jun 25

SMS Pharmaceuticals Boosts Ownership in SMS Peptides to 99.98%

SMS Pharmaceuticals has raised its ownership in its subsidiary, SMS Peptides, from 93.00% to 99.98%. This strategic move strengthens SMS Pharmaceuticals' position in the peptides segment and allows for enhanced integration, strategic alignment, and financial consolidation. The increased stake demonstrates the company's commitment to consolidating control over SMS Peptides and positions it to capitalize on emerging opportunities in the growing peptide-based pharmaceuticals market.

25Jun 25

SMS Pharma's Central Laboratory Aces USFDA Inspection

SMS Pharmaceuticals Limited's Central Laboratory Analytical Services successfully passed a recent U.S. Food and Drug Administration (USFDA) inspection without any observations. This achievement demonstrates the company's compliance with USFDA standards, high-quality control processes, and analytical methods. The successful inspection is expected to boost market confidence and potentially open new business opportunities, particularly in the U.S. and other regulated markets.

30May 25

SMS Pharma Receives FDA Clearance for Hyderabad Facility

SMS Pharmaceuticals Limited announced the successful closure of a U.S. FDA inspection at its Hyderabad facility, receiving an Establishment Inspection Report (EIR). This signifies the facility's compliance with FDA standards and good manufacturing practices. The EIR could enhance SMS Pharma's ability to manufacture and export products to the U.S. market, potentially boosting stakeholder confidence and opening new opportunities in the pharmaceutical manufacturing landscape.

30May 25

SMS Pharma Reports Strong Q4 Results with Improved EBITDA and Net Profit

SMS Pharmaceuticals Limited (SMS Pharma) released Q4 financial results showing significant improvements. EBITDA increased to ₹408.00 million from ₹336.00 million year-over-year, with EBITDA margin expanding to 16.45% from 13.68%. Consolidated net profit rose to ₹203.00 million, up from ₹173.00 million year-over-year. Revenue remained stable at ₹2,500.00 million. The results indicate enhanced operational efficiency and cost management despite stable revenue.

02May 25

SMS Pharma's Vizag Plant Achieves WHO Prequalification, Boosting Global Market Prospects

SMS Pharmaceuticals Limited's manufacturing facility in Visakhapatnam has obtained World Health Organization (WHO) prequalification. This certification validates the facility's quality, safety, and efficacy standards, potentially opening doors to global markets and international tenders. The achievement is expected to enhance SMS Pharma's competitive position, boost customer confidence, and create opportunities for revenue growth and market expansion in the global pharmaceutical supply chain.

24Mar 25

SMS Pharmaceuticals Concludes USFDA Inspection at Hyderabad API Facility with Minor Observation

SMS Pharmaceuticals' API manufacturing facility in Hyderabad, Telangana, has undergone a USFDA inspection. The inspection concluded with Form 483 issued, containing only one observation. This outcome is generally viewed positively in the pharmaceutical industry, suggesting the company's manufacturing practices largely align with U.S. regulatory standards. SMS Pharmaceuticals will need to respond to the observation and provide a plan to address the issue. The nature and severity of the observation remain undisclosed.